{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT06927999","orgStudyIdInfo":{"id":"EPI U02"},"organization":{"fullName":"ARS Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria","officialTitle":"An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-07-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-04-04","studyFirstSubmitQcDate":"2025-04-07","studyFirstPostDateStruct":{"date":"2025-04-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-29","lastUpdatePostDateStruct":{"date":"2025-10-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"ARS Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares)."},"conditionsModule":{"conditions":["Urticaria Chronic"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":42,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo solution nasal spray containing no active drug will be administered using the commercial sprayer device.","interventionNames":["Drug: Placebo"]},{"label":"0.5 mg","type":"ACTIVE_COMPARATOR","description":"0.5 mg epinephrine per spray","interventionNames":["Drug: 0.5 mg epinephrine"]},{"label":"1 mg","type":"ACTIVE_COMPARATOR","description":"1 mg epinephrine per spray","interventionNames":["Drug: 1 mg epinephrine"]}],"interventions":[{"type":"DRUG","name":"Placebo","description":"Placebo solution nasal spray containing no active drug","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"0.5 mg epinephrine","description":"0.5 mg epinephrine per spray","armGroupLabels":["0.5 mg"]},{"type":"DRUG","name":"1 mg epinephrine","description":"1 mg epinephrine per spray","armGroupLabels":["1 mg"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch and hive","description":"Change in itch and hive scores (Uniform Assessment System) \\[UAS\\] as compared to placebo at each timepoint on exacerbation days","timeFrame":"12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is a male or female between the ages of 18 and 65 years, inclusive.\n* Has been clinically diagnosed with CSU and experiences an acute flare of moderate to severe urticaria symptoms (itch and hive severity UAS score ≥ 2) approximately 1-2 times a month or every other month consistently during the past year while on a chronic treatment.\n* Has been on a daily chronic treatment for ≥ 6 weeks.\n* Is willing to use a smartphone study application to record study assessments and AEs.\n* Has body weight more than 15 kilogram (kg).\n* Has no medical history of clinically significant hypertension and cardiovascular disease in the last 10 years\n* If female, is not pregnant or breastfeeding based on a negative urine pregnancy test at baseline.\n* Is able to communicate clearly with the Investigator and staff; able to read, complete questionnaires, and perform study procedures on the smartphone study application.\n* Is willing and able to provide written informed consent prior to participating in the study.\n* Controlled hypertension without beta blocker confirmed by the Investigator is acceptable.\n* At screening, has stable vital signs in the following ranges (after 5 minutes of rest):\n\n  * Systolic blood pressure (SBP) ≥90 and ≤140 milliliters of mercury (mmHg)\n  * Diastolic blood pressure (DBP) ≥50 and ≤90 mmHg\n  * Heart rate (HR) ≥45 and ≤100 beats per minute (bpm)\n\nExclusion Criteria:\n\n* Has a history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.\n* Has any clinically significant medical condition or PE finding as deemed inappropriate by the Investigator.\n* Has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal electrocardiogram (ECG)\n* Has had significant traumatic injury or major surgery within 30 days prior to study screening.\n* Known hypersensitivity to any compound in the test product, or any other closely related compound (e.g., dihydropyridine-derived molecules).\n* Has participated in a clinical trial within 30 days prior to the first dose of study drug.\n* Has an immediate family member of the Investigator, or an employee of the study center, with direct involvement in the proposed study, or other studies under the direction of the Investigator or study center or is in a dependent relationship with a study center employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling), or may consent under duress.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Osnat Ehrman, MSc","role":"CONTACT","phone":"952.334.5797","email":"osnate@pacificlinkconsulting.com"}],"locations":[{"facility":"Endeavor Health Clinical Trials Center","status":"RECRUITING","city":"Glenview","state":"Illinois","zip":"60026","country":"United States","contacts":[{"name":"Giselle Mosnaim, MD","role":"CONTACT","phone":"847-998-4170","email":"Gmosnaim@northshore.org"}],"geoPoint":{"lat":42.06975,"lon":-87.78784}},{"facility":"Bernstein Clinical Research Center, LLC","status":"RECRUITING","city":"Cincinnati","state":"Ohio","zip":"45236","country":"United States","contacts":[{"name":"Jonathan A. Bernstein","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Institute of Allergology IFA Charité - Campus Benjamin Franklin | Hindenburgdamm 30","status":"NOT_YET_RECRUITING","city":"Berlin","zip":"12203","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D000080223","term":"Chronic Urticaria"}],"ancestors":[{"id":"D014581","term":"Urticaria"},{"id":"D017445","term":"Skin Diseases, Vascular"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D006969","term":"Hypersensitivity, Immediate"},{"id":"D006967","term":"Hypersensitivity"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D002908","term":"Chronic Disease"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D004837","term":"Epinephrine"}],"ancestors":[{"id":"D004983","term":"Ethanolamines"},{"id":"D000605","term":"Amino Alcohols"},{"id":"D000438","term":"Alcohols"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D000588","term":"Amines"},{"id":"D015306","term":"Biogenic Monoamines"},{"id":"D001679","term":"Biogenic Amines"},{"id":"D002395","term":"Catecholamines"},{"id":"D002396","term":"Catechols"},{"id":"D010636","term":"Phenols"},{"id":"D001555","term":"Benzene Derivatives"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06834165","orgStudyIdInfo":{"id":"EPI R01"},"organization":{"fullName":"ARS Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy","officialTitle":"A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-05-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-02-18","studyFirstSubmitQcDate":"2025-02-18","studyFirstPostDateStruct":{"date":"2025-02-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-24","lastUpdatePostDateStruct":{"date":"2025-10-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"ARS Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention."},"conditionsModule":{"conditions":["Allergic Reactions"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":600,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Neffy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Neffy"]},{"label":"IM adrenaline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Adrenaline"]}],"interventions":[{"type":"DRUG","name":"Neffy","description":"Epinephrine nasal spray","armGroupLabels":["Neffy"]},{"type":"DRUG","name":"Adrenaline","description":"Epinephrine injection","armGroupLabels":["IM adrenaline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"AEs after epinephrine treatment within 2 hours","timeFrame":"2 hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is a patient 4 years old or greater, inclusive, who are scheduled to undergo OFC, AIT, or other relevant allergy challenge.\n* Has body weight 15 kg or greater at the time of allergy challenge.\n* Is willing and able to provide written informed consent prior to participating in the study. In the case of minors (\\<18 years old), assent can be obtained from his/her legal representative, and as much possible from the patient himself/herself.\n* Patient experiences an allergic reaction that, in the opinion of the Investigator, requires treatment with epinephrine via neffy or IM Adrenalin.\n\nExclusion Criteria:\n\n\\- Has any clinically significant medical condition that precludes treatment with epinephrine as assessed by the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Osnat Ehrman, MSc.","role":"CONTACT","phone":"952.334.5797","email":"osnate@pacificlinkconsulting.com"}],"locations":[{"facility":"Orso Health, Inc.","status":"RECRUITING","city":"La Jolla","state":"California","zip":"92037","country":"United States","contacts":[{"name":"Investigator, MD","role":"CONTACT","phone":"858-260-2977","email":"adoroudchi@modena-health.com"},{"name":"Ali Doroudchi, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Cincinnati Children's Hospital Medical Center","status":"RECRUITING","city":"Cincinnati","state":"Ohio","zip":"45229","country":"United States","contacts":[{"name":"Investigator, MD","role":"CONTACT","phone":"513-517-1179","email":"Yasmin.hassoun@cchmc.org"},{"name":"Yasmin Hassoun, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.12711,"lon":-84.51439}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D006967","term":"Hypersensitivity"}],"ancestors":[{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D004837","term":"Epinephrine"}],"ancestors":[{"id":"D004983","term":"Ethanolamines"},{"id":"D000605","term":"Amino Alcohols"},{"id":"D000438","term":"Alcohols"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D000588","term":"Amines"},{"id":"D015306","term":"Biogenic Monoamines"},{"id":"D001679","term":"Biogenic Amines"},{"id":"D002395","term":"Catecholamines"},{"id":"D002396","term":"Catechols"},{"id":"D010636","term":"Phenols"},{"id":"D001555","term":"Benzene Derivatives"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"}]}},"hasResults":false}
]}